Ignyte Acquisition Corp. Completes Business Combination with Peak Bio Co., Ltd.

Invaio Sciences Acquires Peptyde Bio

December 7, 2023

Biotechnology

Invaio Sciences has acquired Peptyde Bio, a Danforth Technology Company spinout that discovers and designs antimicrobial peptides for crop protection. The deal brings Peptyde Bio’s peptide discovery platform and IP into Invaio’s AI-enabled discovery engine and biological delivery systems to accelerate nature-positive crop protection solutions.

BioNTech Acquires Biotheus

February 3, 2025

Biotechnology

BioNTech SE has completed the acquisition of clinical-stage biotechnology company Biotheus for $800 million in cash and ADS consideration plus up to $150 million in milestone payments. The deal gives BioNTech full global rights to BNT327 and Biotheus' antibody platform, and adds a local R&D hub and biologics manufacturing facility in China to BioNTech's network to support its oncology strategy.

Cinven Acquires Majority Stake in BioAgilytix; Cobepa Reinvests

December 20, 2021

Healthcare Services

International private equity firm Cinven has agreed to acquire a majority stake in BioAgilytix through a recapitalization, with current investor Cobepa remaining a significant minority investor. GHO Capital has realised its investment and will exit; the transaction will provide funding to support BioAgilytix’s international expansion, capacity and capability investments, and buy-and-build strategy in large-molecule bioanalytical services. BioAgilytix is headquartered in Durham, North Carolina and employs about 870 staff across the United States, Europe and Australia.

Pfizer Completes Acquisition of Biohaven Pharmaceutical Holding Company Ltd.

October 3, 2022

Biotechnology

Pfizer completed its acquisition of Biohaven Pharmaceutical Holding Company Ltd., the maker of NURTEC ODT (rimegepant). The all-cash transaction is valued at approximately $11.6 billion and makes Biohaven a wholly owned subsidiary of Pfizer.

Ginkgo Bioworks to Become Public Company via Business Combination with Soaring Eagle Acquisition Corp

May 11, 2021

AI & Machine Learning

Ginkgo Bioworks agreed to a business combination with special purpose acquisition company Soaring Eagle Acquisition Corp., which would result in Ginkgo becoming a publicly listed company. The transaction is expected to close in the third quarter of 2021 and is expected to provide up to $2.5 billion of gross cash proceeds, including $775 million from a PIPE.

Quanterix Completes Acquisition of Akoya Biosciences

July 8, 2025

Healthcare Services

Quanterix completed its previously announced acquisition of Akoya Biosciences under the amended merger agreement, issuing about 7.8 million shares and paying about $20 million in cash in the aggregate to Akoya holders. The companies positioned the deal as creating an integrated platform for measuring biomarkers across the blood and tissue continuum and expanding addressable markets.